Arcturus Therapeutics Raises $5M in Series A Funding

Arcturus Therapeutics, Inc., a La Jolla, Calif.-based developer of RNAi technologies for the treatment of rare orphan diseases, raised $5m in Series A funding.

The round was led by private capital, high net-worth investors from Canada, Japan and the United States.

The company intends to use the funds to nominate its first clinical candidate in 2014, and recruit staff to expand its operations at the Janssen Labs in La Jolla.

Founded in 2013 and led by Pad Chivukula, chief operating officer and Joseph E. Payne, president and CEO, Arcturus Therapeutics develops nanoparticle siRNA drug delivery systems and is committed to the commercialization of new pharmaceuticals through the combination of in-house discovery and development, pharmaceutical partnerships and licensed commercial rights.



Join the discussion